SNCA
Alpha-synuclein
As of the edition of 20 October 2026, SNCA (alpha-synuclein, UniProt P37840) has 5 drugs tested at it and 7 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P37840
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 253
- Disease areas
- Nervous system; Mental health
- Registered trials of its drugs
- 21
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Emrusolmin | Active | Phase 2 | none listed |
| Prasinezumab | Active | Phase 3 | none listed |
| Minzasolmin | Stopped | Phase 2 | none listed |
| Cinpanemab | Stopped | Phase 2 | none listed |
| NPT200-11 | Went quiet | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 4 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Neuropore Therapies | Route A |
| UCB | Route A |
| Biogen | Route A |
The other 4 companies at SNCA
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at SNCA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.